Business Wire
27 Oct 2025, 19:06 UTC · 46w ago
Verdict
Headline takes no side. We score EW +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The ENCIRCLE single-arm pivotal trial for mitral and tricuspid therapies achieved all primary and secondary endpoints for safety and effectiveness.
So whatSuccessful pivotal trial data typically accelerates regulatory approval and commercial adoption of high-margin medical devices.
More positive than 91% of claims this week
One-year data from the ENCIRCLE trial was published in The Lancet.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
Edwards Lifesciences released thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement study.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company announced successful patient outcomes and the achievement of all primary and secondary endpoints in a pivotal trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1d ago
+16.3%
Price agrees with the score
$88.47 vs $76.10 close before publication (Oct 24) · not market-adjusted
EW chart →
